LSTA — Lisata Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $21.36m
- -$0.86m
- $1.00m
- 21
- 24
- 64
- 28
Annual income statement for Lisata Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 52 W | 52 W | 52 W | 52 W | 52 W |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 19.1 | 29.1 | 57.6 | 25.7 | 23.4 |
| Operating Profit | -19.1 | -29.1 | -57.6 | -25.7 | -22.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19 | -29 | -56.7 | -23.2 | -20.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.14 | -27.5 | -54.2 | -20.8 | -20 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.15 | -27.5 | -54.2 | -20.8 | -20 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.15 | -27.5 | -54.2 | -20.8 | -20 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -7.92 | -7.45 | -10.5 | -2.58 | -2.4 |